Skip to main content

Redmile Group, LLC

SEC CIK
0001425738
Latest filing
Aug 14, 2026

TCRR holding history

TCR2 Therapeutics Inc. in every 13F filed by Redmile Group, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TCRR overviewAll 13F holders of TCRRFull Q2 2026 holdings

Shares (Q2 2023)
0
Sold out in Q2 2023
Value
$0
% of portfolio
0.0%
Quarters held
9
Since Q1 2021
Holdings of TCRR by Redmile Group, LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20230$00.0%−658,336−100.0%Sold outHolders
Q1 2023658,336$987.5K<0.1%−73,043−10.0%ReducedHolders
Q4 2022731,379$730.5K<0.1%−363,266−33.2%ReducedHolders
Q3 20221,094,645$1.97M0.1%00.0%UnchangedHolders
Q2 20221,094,645$3.17M0.1%00.0%UnchangedHolders
Q1 20221,094,645$3.02M0.1%−251,413−18.7%ReducedHolders
Q4 20211,346,058$6.27M0.1%−2,470,651−64.7%ReducedHolders
Q3 20213,816,709$32.5M0.6%+580,900+18.0%AddedHolders
Q2 20213,235,809$53.1M0.8%−374,979−10.4%ReducedHolders
Q1 20213,610,788$79.7M1.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.